Evidence map›Paper›PMID 40855096›Full record

ArticleScientific reports2025

A whole slide image-based risk score predicts prognosis and postmastectomy radiotherapy benefit in triple negative breast cancer patients.

Hong Chen, Lizhi Zhang, Pei Liu, Luping Ji, Chuanxu Luo, Bo Peng, Ting Luo, Feng Ye, Xiaorong Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hong Chen *Department of Pathology, Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology (NHFPC), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lizhi Zhang *Image Processing and Parallel Computing Laboratory, School of Computer Science and Software Engineering, Southwest Petroleum University, Chengdu, 610500, China.
Pei LiuSchool of Computer Science and Engineering, University of Electronic Science and Technology of China, Xiyuan Ave, Chengdu, 611731, China.
Luping JiSchool of Computer Science and Engineering, University of Electronic Science and Technology of China, Xiyuan Ave, Chengdu, 611731, China.
Chuanxu LuoDepartment of Oncology, The Third Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital, Chengdu, 611730, China.
Bo PengImage Processing and Parallel Computing Laboratory, School of Computer Science and Software Engineering, Southwest Petroleum University, Chengdu, 610500, China.
Ting LuoInstitute for Breast Health Medicine, Cancer Center, Breast Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, China.
Feng YeDepartment of Pathology, Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology (NHFPC), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiaorong ZhongInstitute for Breast Health Medicine, Cancer Center, Breast Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, China. zhongxiaorong@126.com.

Funding

Roche Pharmaceuticals Ltd. SL45024Science and Technology of Sichuan Province 2023YFH0095West China Hospital, Sichuan University 2024HXBH034West China Hospital, Sichuan University ZYGX2022YGRH015West China Hospital, Sichuan University ZYJC21035
6 · The paper itself

Abstract

There are few tools support postmastectomy radiotherapy (PMRT) decisions for triple-negative breast cancer (TNBC) patients. This study aimed to develop a whole slide image (WSI)-based risk score to identify PMRT beneficiaries. We analyzed 608 TNBC patients treated at West China Hospital, Sichuan University (WCH) and 182 patients from The Cancer Genome Atlas (TCGA), diagnosed between 2011 and 2019. Utilizing features extracted from hematoxylin and eosin-stained WSI and clinicopathological characteristics, an image score and a clinicopathological score for each patient were computed via eXtreme Gradient Boosting, combined into a comprehensive risk score. Multivariate Cox proportional hazards regression analyses revealed a higher image score strongly associated with worse 5-year invasive disease-free survival (iDFS) (HR = 8.80, P < 0.001), overall survival (OS) (HR = 9.02, P < 0.001), and locoregional recurrence-free survival (LRFS) (HR = 8.39, P = 0.003). The integrated risk score outperformed clinicopathological score in prognostic accuracy, as evidenced by the area under the curve (WCH validation cohort, iDFS: 0.805 vs. 0.756; OS: 0.874 vs. 0.807; LRFS: 0.957 vs. 0.870; TCGA cohort, iDFS: 0.683 vs. 0.598; OS: 0.685 vs. 0.617). Importantly, PMRT significantly improved OS in "high-risk" patients identified by the risk score, but not in "low-risk" patients in both WCH and TCGA cohorts. These findings suggest that the WSI-based risk score shows promise as a tool for prognostic assessment and guiding PMRT decision-making in TNBC patients.

Indexed as

MastectomyTriple Negative Breast NeoplasmsAdultAgedDisease-Free SurvivalFemaleHumansMiddle AgedPrognosisRadiotherapy, AdjuvantRisk AssessmentPostmastectomy radiotherapyPrognosisTriple-negative breast cancerWhole slide imageXGBoost

Identifiers

PMID40855096
PMCPMC12378970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.